Olfactory Bulb Alpha-synucleinopathy Has High Specificity and Sensitivity for Lewy Body Disorders

Overview

Journal Acta Neuropathol

Specialty Neurology

Date 2008 Nov 5

PMID 18982334

Citations 110

Authors

Thomas G Beach

Charles L White 3rd

Christa L Hladik

Marwan N Sabbagh

Donald J Connor

Holly A Shill

Lucia I Sue

Jeanne Sasse

Jyothi Bachalakuri

Jonette Henry-Watson

Haru Akiyama

Charles H Adler

Affiliations

Soon will be listed here.

Abstract

Involvement of the olfactory bulb by Lewy-type alpha-synucleinopathy (LTS) is known to occur at an early stage of Parkinson's disease (PD) and Lewy body disorders and is therefore of potential usefulness diagnostically. An accurate estimate of the specificity and sensitivity of this change has not previously been available. We performed immunohistochemical alpha-synuclein staining of the olfactory bulb in 328 deceased individuals. All cases had received an initial neuropathological examination that included alpha-synuclein immunohistochemical staining on sections from brainstem, limbic and neocortical regions, but excluded olfactory bulb. These cases had been classified based on their clinical characteristics and brain regional distribution and density of LTS, as PD, dementia with Lewy bodies (DLB), Alzheimer's disease with LTS (ADLS), Alzheimer's disease without LTS (ADNLS), incidental Lewy body disease (ILBD) and elderly control subjects. The numbers of cases found to be positive and negative, respectively, for olfactory bulb LTS were: PD 55/3; DLB 34/1; ADLS 37/5; ADNLS 19/84; ILBD 14/7; elderly control subjects 5/64. The sensitivities and specificities were, respectively: 95 and 91% for PD versus elderly control; 97 and 91% for DLB versus elderly control; 88 and 91% for ADLS versus elderly control; 88 and 81% for ADLS versus ADNLS; 67 and 91% for ILBD versus elderly control. Olfactory bulb synucleinopathy density scores correlated significantly with synucleinopathy scores in all other brain regions (Spearman R values between 0.46 and 0.78) as well as with scores on the Mini-Mental State Examination and Part 3 of the Unified Parkinson's Disease Rating Scale (Spearman R -0.27, 0.35, respectively). It is concluded that olfactory bulb LTS accurately predicts the presence of LTS in other brain regions. It is suggested that olfactory bulb biopsy be considered to confirm the diagnosis in PD subjects being assessed for surgical therapy.

Citing Articles

Olfactory Dysfunction in Parkinson's Disease, Its Functional and Neuroanatomical Correlates.

Torres-Pasillas G, Chi-Castaneda D, Carrillo-Castilla P, Marin G, Hernandez-Aguilar M, Aranda-Abreu G NeuroSci. 2024; 4(2):134-151.

PMID: 39483318 PMC: 11523736. DOI: 10.3390/neurosci4020013.

Intercellular transmission of alpha-synuclein.

Wu S, Schekman R Front Mol Neurosci. 2024; 17:1470171.

PMID: 39324117 PMC: 11422390. DOI: 10.3389/fnmol.2024.1470171.

Resistance to high-fat diet-induced weight gain in transgenic mice overexpressing human wild-type α-synuclein: A model for metabolic dysfunction in Parkinson's disease.

Biju K, Hernandez E, Stallings A, Felix-Ortiz A, Hebbale S, Norton L Res Sq. 2024; .

PMID: 39257980 PMC: 11384802. DOI: 10.21203/rs.3.rs-4870881/v1.

Current insights and assumptions on α-synuclein in Lewy body disease.

Leak R, Clark R, Abbas M, Xu F, Brodsky J, Chen J Acta Neuropathol. 2024; 148(1):18.

PMID: 39141121 PMC: 11324801. DOI: 10.1007/s00401-024-02781-3.

Alpha Synuclein Toxicity and Non-Motor Parkinson's.

Mazzotta G, Conte C Cells. 2024; 13(15.

PMID: 39120295 PMC: 11311369. DOI: 10.3390/cells13151265.

References

Cornford M, Chang L, Miller B . The neuropathology of parkinsonism: an overview. Brain Cogn. 1995; 28(3):321-41. DOI: 10.1006/brcg.1995.1261. View

Pearce R, Hawkes C, Daniel S . The anterior olfactory nucleus in Parkinson's disease. Mov Disord. 1995; 10(3):283-7. DOI: 10.1002/mds.870100309. View

. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging. 1997; 18(4 Suppl):S1-2. View

Obeso J, Rodriguez M, Gorospe A, Guridi J, Alvarez L, Macias R . Surgical treatment of Parkinson's disease. Baillieres Clin Neurol. 1997; 6(1):125-45. View

Litvan I, MacIntyre A, Goetz C, Wenning G, Jellinger K, Verny M . Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998; 55(7):969-78. DOI: 10.1001/archneur.55.7.969. View

Gelb D, Oliver E, Gilman S . Diagnostic criteria for Parkinson disease. Arch Neurol. 1999; 56(1):33-9. DOI: 10.1001/archneur.56.1.33. View

Adler C . Nonmotor complications in Parkinson's disease. Mov Disord. 2005; 20 Suppl 11:S23-9. DOI: 10.1002/mds.20460. View

McKeith I, Dickson D, Lowe J, Emre M, OBrien J, Feldman H . Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005; 65(12):1863-72. DOI: 10.1212/01.wnl.0000187889.17253.b1. View

Bloch A, Probst A, Bissig H, Adams H, Tolnay M . Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol. 2006; 32(3):284-95. DOI: 10.1111/j.1365-2990.2006.00727.x. View

10.

Hawkes C . Olfaction in neurodegenerative disorder. Adv Otorhinolaryngol. 2006; 63:133-151. DOI: 10.1159/000093759. View

11.

Lang A, Houeto J, Krack P, Kubu C, Lyons K, Moro E . Deep brain stimulation: preoperative issues. Mov Disord. 2006; 21 Suppl 14:S171-96. DOI: 10.1002/mds.20955. View

12.

Paluzzi A, Belli A, Bain P, Liu X, Aziz T . Operative and hardware complications of deep brain stimulation for movement disorders. Br J Neurosurg. 2006; 20(5):290-5. DOI: 10.1080/02688690601012175. View

13.

Braak H, Bohl J, Muller C, Rub U, de Vos R, Del Tredici K . Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord. 2006; 21(12):2042-51. DOI: 10.1002/mds.21065. View

14.

Master Z, McLeod M, Mendez I . Benefits, risks and ethical considerations in translation of stem cell research to clinical applications in Parkinson's disease. J Med Ethics. 2007; 33(3):169-73. PMC: 2598267. DOI: 10.1136/jme.2005.013169. View

15.

Gill C, Konrad P, Davis T, Charles D . Deep brain stimulation for Parkinson's disease: the Vanderbilt University Medical Center experience, 1998-2004. Tenn Med. 2007; 100(4):45-7. View

16.

Hubbard P, Esiri M, Reading M, McShane R, Nagy Z . Alpha-synuclein pathology in the olfactory pathways of dementia patients. J Anat. 2007; 211(1):117-24. PMC: 2375794. DOI: 10.1111/j.1469-7580.2007.00748.x. View

17.

Seijo F, Alvarez-Vega M, Gutierrez J, Fdez-Glez F, Lozano B . Complications in subthalamic nucleus stimulation surgery for treatment of Parkinson's disease. Review of 272 procedures. Acta Neurochir (Wien). 2007; 149(9):867-75. DOI: 10.1007/s00701-007-1267-1. View

18.

Tir M, Devos D, Blond S, Touzet G, Reyns N, Duhamel A . Exhaustive, one-year follow-up of subthalamic nucleus deep brain stimulation in a large, single-center cohort of parkinsonian patients. Neurosurgery. 2007; 61(2):297-304. DOI: 10.1227/01.NEU.0000285347.50028.B9. View

19.

Rodriguez R, Fernandez H, Haq I, Okun M . Pearls in patient selection for deep brain stimulation. Neurologist. 2007; 13(5):253-60. DOI: 10.1097/NRL.0b013e318095a4d5. View

20.

McKinnon J, Demaerschalk B, Caviness J, Wellik K, Adler C, Wingerchuk D . Sniffing out Parkinson disease: can olfactory testing differentiate parkinsonian disorders?. Neurologist. 2007; 13(6):382-5. DOI: 10.1097/NRL.0b013e31815a351a. View